On the 2025 Kidney Most cancers Analysis Summit, Dr. Wenxin (Vincent) Xu sat down for an interview with CURE, by which, he mentioned the advantage of utilizing biomarkers to information remedy for renal cell carcinoma (a sort of kidney most cancers).
“Should you [are able] to know at [ahead of time] that your remedy is just not going effectively, these sufferers may do significantly better should you’re capable of swap tracks early,” Xu emphasised within the interview.
In the course of the dialog, he aimed to clarify to sufferers what KIM-1 is, and the way biomarkers like this can be utilized as a possible therapeutic goal to information kidney most cancers remedy extra exactly.
Xu is a doctor, medical oncologist and medical trial investigator within the Lank Heart Genitourinary Oncology at Dana-Farber Most cancers Institute, in addition to an assistant professor of medication at Harvard Medical College, each positioned in Boston.
Transcript
How may KIM-1 be used to information kidney most cancers remedy extra exactly sooner or later?
There are a lot of methods we may think about utilizing a blood take a look at for kidney most cancers, and what I will focus on usually are not the one ones. A number of the apparent methods this may very well be useful are, for instance, we all know that adjuvant immunotherapy after surgical procedure improves affected person survival. However whenever you actually break it down, out of all of the sufferers you are treating with adjuvant immunotherapy, solely 8% are sufferers who’re cured and wouldn’t have already been cured by the surgical procedure.
It is a small variety of sufferers you are benefiting by treating a big quantity. Hopefully, if in case you have a extra exact biomarker, we are able to slender that down and keep away from giving further remedy to sufferers who do not want it, and maybe additionally determine which sufferers are at a extremely excessive threat and provides further remedy to forestall recurrence in these sufferers. In order that’s simply certainly one of some ways a blood take a look at may very well be helpful.
One other approach, for instance, is that if a affected person has metastatic kidney most cancers and so they’re being handled with immunotherapy. You may think about that that affected person may need to know earlier — earlier than the same old 12-week scan — whether or not the remedy is working or not. As a result of should you may know at three weeks as an alternative of 12 weeks that your remedy is absolutely not going effectively, these sufferers may do significantly better should you’re capable of swap tracks early.
This piece displays the writer’s private expertise and perspective. For medical recommendation, please seek the advice of your well being care supplier.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
